Medclair AB (NGM:MCLR) Price-to-Funds-From-Operations: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:MCLR Medclair AB NGM:MCLR
71 GF Score
Price kr2.82
GF Value kr2.24
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medclair AB Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

NGM:MCLR
71GF Score
Medclair AB NGM:MCLR
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medclair AB (NGM:MCLR) Overvalued in 2026?

Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued. The current stock price of kr2.82 is trading 25.9% above its estimated GF Value™ of kr2.24. GuruFocus considers Medclair AB to be Modestly Overvalued.

Key valuation signals for NGM:MCLR:

  • Price-to-Funds-From-Operations:
  • GF Value™: kr2.24 vs. price of kr2.82 (25.9% above fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medclair AB Business Description

Address Fraktflygargatan 1, Stockholm, SWE, 128 30
Medclair AB is a Swedish medical technology company focused on reducing emissions of nitrous oxide (laughing gas) used for pain relief in healthcare. Its core products are nitrous oxide destruction units, including the Central Destruction Unit (CDU) for fixed installations and the Mobile Destruction Unit (MDU) for portable use, which catalytically decompose exhaled nitrous oxide into nitrogen and oxygen. The company also supplies complementary delivery and scavenging solutions such as double masks, single masks, mouthpieces, and free-flow systems, designed to protect healthcare professionals from occupational exposure. Its customers are primarily hospitals, maternity wards, dental clinics, and other healthcare providers in Sweden and other European markets. Revenue is generated mainly through sales of destruction units and related consumables, masks, and accessories, along with service, installation, and maintenance agreements. Medclair thus addresses both workplace safety and environmental concerns associated with nitrous oxide use.
71GF Score

Get the complete analysis for NGM:MCLR

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.82
Price
kr2.24
GF Value